Drug combination acts against aggressive chronic lymphocytic leukemia Oncology Nurse Advisor This phase II study enrolled 40 patients with high-risk CLL, who received daily oral doses of 420 mg ibrutinib throughout treatment, weekly infusions of 375 mg/m2 rituximab during weeks 1 through 4, and monthly rituximab infusions for the next 5 months. |
